Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy
J. P. Zhang(Dana-Farber Cancer Institute), Maximilian Stahl(Harvard University), Eno Inyang(Dana-Farber Cancer Institute), Luis E. Aguirre(Harvard University), Shai Shimony(Twitter (United States)), Evan C. Chen(Dana-Farber Cancer Institute), Rebecca P. Bystrom(Dana-Farber Cancer Institute), Benjamin Rolles(Brigham and Women's Hospital), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Emily Tiao(Dana-Farber Cancer Institute), Yiwen Liu(University of Arizona)
Cited by 0
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825